Actelion and Johnson&Johnson have entered into a definitive agreement whereby Actelion shareholders will receive USD280 (CHF280.08) per share in cash and a share in the new spun-off R&D company (drug discovery operations and early-stage clinical development assets), to be listed on the Swiss market and in which J&J will initially hold 16%. The tender offer is expected to start by mid-February.

26 Jan 2017
Johnson&Johnson to acquire Actelion with a huge premium

Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Johnson&Johnson to acquire Actelion with a huge premium
Actelion and Johnson&Johnson have entered into a definitive agreement whereby Actelion shareholders will receive USD280 (CHF280.08) per share in cash and a share in the new spun-off R&D company (drug discovery operations and early-stage clinical development assets), to be listed on the Swiss market and in which J&J will initially hold 16%. The tender offer is expected to start by mid-February.